Thanks to Chuck Grohoski of OnPoint Consulting for the dinner invitation at Lucrezia La Jolla on Tuesday evening during the Optimizing Clinical Trials conference. Great food and amazing company make for an enjoyable evening. Joining us were a group of Pharm executives including Anni Li of Tasly Pharma, Roberta Alexander of UCSD, and Gajanan Bhat of TORL.
关于我们
Coronavax, Inc., is a Biotechnology company in Orange, CA, developing a new immunotherapy for Long COVID. Long COVID is a critical unmet medical need, with an estimated 20 Million persons and 100 Million worldwide suffering from the condition. Currently, there are few effective treatments available for Long COVID, with rehabilitative care helping people recover. Cancer immunotherapy has become a success for patients and investors. Instead of highly toxic chemotherapy drugs, this new technology teaches the immune system how to locate, recognize, and kill tumor cells. Each year, immunotherapy approaches have gained regulatory approval for new types of cancer. The leading theory behind Long COVID is that in many cases, the SARS-2 virus is not being eliminated from the body. Infections like HIV and Herpes, and Epstein-Barr virus are examples where the immune response is unable to clear the infection. At Coronavax, we are applying the science of cancer immunotherapy to Long COVID. Our lead product, CVAX-001, is a Lipid Nanoparticle containing SARS-2 spike proteins from three major strains. CVAX-001 is administered via intranasal spray to induce anti-inflammatory mucosal responses. The goal is to eliminate infected cells and residual virus without triggering excess inflammation. CVAX-001 has been manufactured and tested in mice and hamsters. It has not been tested in human clinical trials. We believe that by applying the science of immunotherapy to Long COVID, we can help millions of people to resume a normal, healthy life.
- 网站
-
https://coronavax.net/
Coronavax Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 私人持股
- 创立
- 2021
- 领域
- Biotechnology、Long COVID、COVID-19、Public Health、Immunotherapy 、Scientific Research、Infectious Disease 、Immunology和Virology
Coronavax Inc.员工
动态
-
Coronavax, Inc. is bringing the science of cancer immunotherapy to Long COVID. To learn more, or help with our latest Reg. C equity CF raise, click:?https://lnkd.in/gWKvS-Pn
-
-
Military pilots reported a 1,700% increase in medical incidents during the Pandemic according to the Pentagon:?https://lnkd.in/gSHjbqEw
-
A frequently asked question is how many viruses are required for infection? Theoretically, one virus can infect a cell and produce thousands. Practically, we know that between 1,000 and 50,000 virus particles are required to infect hamsters:?https://lnkd.in/gMUBEiqK
-
Researchers at Mt. Sinai and U. of Virginia found that arthritis medications can help reverse COVID lung fibrosis damage from COVID:?https://lnkd.in/gWXjKZUZ
-
Dr. Phillip Avelda, DARPA Manager who worked on Operation Warp Speed, which developed mRNA vaccine, says that at current rates of infection most Americans will develop LC over lifetime. https://lnkd.in/gKuzziPh
-
Dr. Phillip Avelda, DARPA Manager who worked on Operation Warp Speed, which developed mRNA vaccine, says that at current rates of infection most Americans will develop LC over lifetime?https://lnkd.in/gKuzziPh
-
An ominous report from Miami describes two infants born to mothers infected with SARS-2 tested positive for virus that had crossed the placenta and infected their brains: https://lnkd.in/gUKAedJj
-
A paper by Harvard Med. School team describes the intense inflammation activation gene signatures seen in persons with Long Covid. This is combined with dysfunctional responses by the adaptive/specific T and B cell responses. By jamming your immune system into 1st gear with the pedal to the metal, the virus persists, establishing “Squatters Rights” : https://lnkd.in/gAq4ww-6
-
Intriguing article from Spain details how immune imprinting and recall responses to previous infections with common cold coronaviruses can derail effective immune responses to SARS-2:https://lnkd.in/g_pmZXwD